TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic failure. Subtle inter-patient genetic variation and environmental factors combine to determine variation in disease progression. A common non-synonymous polymorphism in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys) was recently associated with increased hepatic triglyceride content, but whether this variant promotes clinically relevant hepatic fibrosis is unknown. Here we confirm that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN . Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n =1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis. These findings establish new and important clinical relevance to TM6SF2 in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The rs58542926 minor allele of transmembrane 6 superfamily member 2 (TM6SF2) is also reportedly associated with MASLD and sometimes MASH (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, the splice variant rs72613567 in the Hydroxysteroid 17-beta Dehydrogenase 13 (HSD17B13) gene has been identified as protective against MASH, with HSD17B13 potentially contributing to MASH fibrosis by promoting pyrimidine catabolism (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies
Edmondson, H. A., & Steiner, P. E. (1954) · Cancer · doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e · Cited by 2,772
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Purcell, S., Cherny, S. S., & Sham, P. C. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.1.149 · Cited by 2,057
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Self-citation
Cited by
Items 201–300 of 623
Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications
Martin, K., Hatab, A., Athwal, V. S., Jokl, E. J., & Hanley, K. P. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01377-5 · Cited by 48
Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA
Campani, C., Zucman‐Rossi, J., & Nault, J. (2023) · Cancers · doi:10.3390/cancers15030817 · Cited by 54
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Argenziano, M. E., Kim, M. N., Montori, M., Bucchianico, A. D., Balducci, D., Ahn, S. H., & Svegliati‐Baroni, G. (2024) · Hepatology International · doi:10.1007/s12072-024-10692-4 · Cited by 60
Kim, S., Oh, J. S., Shin, J. I., Aalruz, H., Abbas, N., Babatope, A. E., Aboagye, R. G., Abohashem, S., Abu‐Zaid, A., Addo, I. Y., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00011-7 · Cited by 82
Gentilucci, U. V., Gallo, P., Dell’Unto, C., Volpentesta, M., Incalzi, R. A., & Picardi, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i43.4835 · Cited by 48
Yenilmez, B., Wetoska, N., Kelly, M., Echeverria, D., Min, K., Lifshitz, L., Alterman, J. F., Hassler, M. R., Hildebrand, S., DiMarzio, C., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.007 · Cited by 46
Marzuillo, P. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i11.1439 · Cited by 48
Non-alcoholic fatty liver disease: a narrative review of genetics
Christopher, J., Zemin, Y., & Z., G. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.32.20180045 · Cited by 45
“Similar to the PNPLA3 I148M variant, the TM6SF2 E1267K variant not only increases the risk of steatosis, but has also been associated with increased risk of progressive liver disease and fibrosis([20]).”
BackgroundResultPal, P., Palui, R., & Ray, S. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1584 · Cited by 55
MAFLD: an optimal framework for understanding liver cancer phenotypes
Crane, H., Gofton, C., Sharma, A., & George, J. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02021-7 · Cited by 51
Traussnigg, S., Kienbacher, C., Gajdošík, M., Valkovič, L., Halilbasic, E., Stift, J., Rechling, C., Hofer, H., Steindl‐Munda, P., Ferenci, P., et al. (2017) · Liver International · doi:10.1111/liv.13451 · Cited by 45
Recent advances in understanding and managing non-alcoholic fatty liver disease
Albhaisi, S., & Sanyal, A. (2018) · F1000Research · doi:10.12688/f1000research.14421.1 · Cited by 45
Lim, H.-W., & Bernstein, D. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.008 · Cited by 49
Screening strategy for non-alcoholic fatty liver disease
Zhang, S., Mak, L., Yuen, M., & Seto, W. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0336 · Cited by 52
The contribution of genetics and epigenetics to MAFLD susceptibility
Moretti, V., Romeo, S., & Valenti, L. V. C. (2024) · Hepatology International · doi:10.1007/s12072-024-10667-5 · Cited by 53
“The TM6SF2 variant also predisposes to the full spectrum of liver damage, that is MASH, severe fibrosis, and HCC [23, 32], but at the same time protects against cardiovascular disease through the reduction in lipoprotein secretion [33].”
BackgroundNon-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
Zhu, B., Chan, S., Li, J., Li, K. S., Wu, H., Cui, K., & Chen, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.742382 · Cited by 54
Rivera‐Esteban, J., Muñoz, S., Higuera, M., Sena, E., Bermúdez-Ramos, M., Bañares, J., Martínez-Gómez, M., Cusidó, M. S., Jiménez-Masip, A., Francque, S., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.028 · Cited by 52
Self-citationGolabi, P., Owrangi, S., & Younossi, Z. M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17833 · Cited by 63
“46,47 Following those two famous genes, many others have been identified to play a role in NAFLD development and severity.”
BackgroundKim, S. K., Ueda, Y., Hatano, E., Kakiuchi, N., Takeda, H., Gotō, T., Shimizu, T., Yoshida, K., Ikura, Y., Shiraishi, Y., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30379 · Cited by 46
The Endless Sources of Hepatocellular Carcinoma Heterogeneity
Bárcena‐Varela, M., & Lujambio, A. (2021) · Cancers · doi:10.3390/cancers13112621 · Cited by 48
“Transmembrane 6 superfamily member 2 (TM6SF2) variants are also strongly associated with the presence of NAFLD and have been correlated with the severity of steatosis, NASH, and cirrhosis [70,71].”
BackgroundGenetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
Pei, Y., & Goh, G. B. (2025) · Gut and Liver · doi:10.5009/gnl240407 · Cited by 52
Long, M. T., Gurary, E. B., Massaro, J. M., Ma, J., Hoffmann, U., Chung, R. T., Benjamin, E. J., & Loomba, R. (2019) · Liver International · doi:10.1111/liv.13956 · Cited by 40
Kallwitz, E. R., Tayo, B. O., Kuniholm, M. H., Cai, J., Daviglus, M. L., Cooper, R., & Cotler, S. J. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.02.007 · Cited by 41
Miao, Z., Garske, K. M., Pan, D. Z., Koka, A., Kaminska, D., Männistö, V., Sinsheimer, J. S., Pihlajamäki, J., & Pajukanta, P. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100056 · Cited by 40
Jiang, Z. G., Tapper, E. B., Connelly, M. A., Pimentel, C. F. M. G., Feldbrügge, L., Kim, M.-S., Krawczyk, S. A., Afdhal, N. H., Robson, S. C., Herman, M. A., et al. (2016) · Liver International · doi:10.1111/liv.13076 · Cited by 40
Emdin, C. A., Haas, M., Khera, A. V., Aragam, K., Chaffin, M., Jiang, L., Wei, W.-Q., Feng, Q., Karjalainen, J., Havulinna, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/594523 · Cited by 40
Lin, Y., Chang, P., Chang, M., & Ni, Y. (2018) · Liver International · doi:10.1111/liv.13689 · Cited by 40
Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease
Taliento, A. E., Dallio, M., Federico, A., Prati, D., & Valenti, L. V. C. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152755 · Cited by 47
“In keeping with these results, another study in a Japanese cohort of patients with NASH showed that the C47T SOD2 variant was more represented in patients with NASH [44].”
BackgroundInfluentialNon-alcoholic fatty liver disease: A review with clinical and pathological correlation
Chen, Y., & Yeh, M. M. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.07.006 · Cited by 50
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022) · Hormones · doi:10.1007/s42000-022-00377-8 · Cited by 39
“88, independent of the PNPLA3 genotype [113].”
Holmer, M., Ekstedt, M., Nasr, P., Zenlander, R., Wester, A., Tavaglione, F., Romeo, S., Kechagias, S., Stål, P., & Hagström, H. (2022) · Liver International · doi:10.1111/liv.15438 · Cited by 38
Goyal, N. P., Rosenthal, S. B., Nasamran, C., Behling, C. A., Angeles, J. E., Fishbein, M. H., Adams, K. H., Jain, A. K., Molleston, J. P., Newton, K. P., et al. (2022) · Hepatology · doi:10.1002/hep.32570 · Cited by 41
“In histologic studies with European adults, this SNP was associated with NASH, severity of steatosis, and severity of fibrosis.[27,35,36] In contrast, in GWAS of 1483 European adults and 17,781 controls, TM6SF2 was associated with the risk of NAFLD, but did not reach significance when evaluated for steatosis, NASH, or…”
BackgroundThe burden of liver disease in Latin America
Díaz, L. A., Villota‐Rivas, M., Francisco Barrera, M., Lazarus, J. V., & Arrese, M. A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101175 · Cited by 52
Chen, L., Xia, H. H., Xin, Y., Lin, Z., & Xuan, S. (2015) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2015.00023 · Cited by 41
“Several studies have confirmed that dietary cholesterol and dysregulated cholesterol metabolism play a crucial role in the development and severity of hepatic inflammation and NASH.41,42 However, another study demonstrated that accumulation of hepatic triglyceride may not be directly hepatotoxic in mice with methionin…”
BackgroundInfluentialp53 as a double-edged sword in the progression of non-alcoholic fatty liver disease
Yan, Z., Miao, X., Zhang, B., & Xie, J. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.051 · Cited by 39
PNPLA3 and obesity: a synergistic relationship in NAFLD
Mann, J. P., & Anstee, Q. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.74 · Cited by 38
Self-citationLi, X., Liu, Z., Li, L., Wang, H., & Wang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1026901 · Cited by 45
TM6SF2: A novel target for plasma lipid regulation
Li, T., Li, T., Peng, J., He, B., Liu, L.-S., Wei, D., Jiang, Z., Zheng, X., & Tang, Z. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.11.033 · Cited by 41
Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer, H., Shibolet, O., & Deutsch, L. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3929 · Cited by 42
Wang, Q., You, H., Ou, X., Zhao, X., Sun, Y., Wang, M., Wang, P., Wang, Y., Duan, W., Wang, X., et al. (2019) · Hepatology International · doi:10.1007/s12072-019-09982-z · Cited by 40
New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease
Lin, Y., Wu, C.-C., & Ni, Y. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.603654 · Cited by 43
“Further studies reported the TM6SF2 rs58542926 variant also influences hepatic fibrosis and metabolic homeostasis (87, 88).”
BackgroundA PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?
Eldafashi, N., Darlay, R., Shukla, R., McCain, M. V., Watson, R., Liu, Y. L., McStraw, N. M., Fathy, M., Fawzy, M. A., Zaki, M. Y. W., et al. (2021) · Cancers · doi:10.3390/cancers13061412 · Cited by 38
Self-citationShao, G., Liu, Y., Lu, L., Zhang, G., Zhou, W., Wu, T., Wang, L., Xu, H., & Ji, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944088 · Cited by 39
Self-citationLiu, Z., Que, S., Zhou, L., Zheng, S., Romeo, S., Mardinoğlu, A., & Valenti, L. V. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-09548-9 · Cited by 43
Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients
Cheung, A. C., Figueredo, C. J., & Rinella, M. E. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000058 · Cited by 41
Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease
Blencowe, M., Karunanayake, T., Wier, J. R., Hsu, N., & Yang, X. (2019) · Genes · doi:10.3390/genes10120966 · Cited by 36
“TM6SF2 has been shown to regulate hepatic triglyceride and serum low density lipoprotein levels, while also being a marker for fibrosis/cirrhosis [42,43].”
BackgroundAhmad, M. I., Khan, M. U., Kodali, S., Shetty, A., Bell, S. M., & Victor, D. W. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s344559 · Cited by 39
“The rs58542926 C > T variant in the TM6SF2 gene, encoding an E167K mutation, is associated with hepatic steatosis and an increased risk of liver fibrosis.(116,117) Its role in HCC development, however, remains uncertain.”
BackgroundHydes, T., Kennedy, O. J., Glyn‐Owen, K., Buchanan, R. M., Parkes, J., Cuthbertson, D. J., Roderick, P., & Byrne, C. D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.045 · Cited by 35
TINIAKOS, D. G., Anstee, Q. M., & Burt, A. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00005-4 · Cited by 37
Self-citationWu, J.-T., Liu, S., Xie, X., Liu, Q., Xin, Y., & Xuan, S. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01207-9 · Cited by 36
PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease
Lisboa, Q. C., Nardelli, M. J., Pereira, P. D. A., de Miranda, D. M., Ribeiro, S. N., da Costa, R. S. N., Versiani, C. A., Vidigal, P. V. T., Ferrari, T. C. A., & Couto, C. A. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i10.792 · Cited by 38
Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis
Kozlitina, J. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.09.001 · Cited by 33
Akuta, N., Kawamura, Y., Arase, Y., Suzuki, F., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., Suzuki, Y., et al. (2015) · Gut and Liver · doi:10.5009/gnl15163 · Cited by 37
“The impact of TM6SF2 genotype on NAFLD is controversial.(15-18) Liu and coworkers(16) reported that TM6SF2 genotype affected necroinflammation score, but they could not replicate this result in their large-scale validation cohort, unfortunately.”
BackgroundInfluentialGenetics of alcoholic liver disease and non-alcoholic steatohepatitis
Scott, E., & Anstee, Q. M. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-2-s54 · Cited by 32
Self-citationGenetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease
Kovalic, A. J., Banerjee, P., Tran, Q. T., Singal, A. K., & Satapathy, S. K. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.04.001 · Cited by 34
Dallio, M., Romeo, M., Gravina, A. G., Masarone, M., Larussa, T., Abenavoli, L., Persico, M., Loguercio, C., & Federico, A. (2021) · Nutrients · doi:10.3390/nu13051679 · Cited by 33
Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
Huang, G., Wallace, D. F., Powell, E. E., Rahman, T. M., Clark, P. J., & Subramaniam, V. N. (2023) · Biomedicines · doi:10.3390/biomedicines11102809 · Cited by 33
Bourganou, M. V., Chondrogianni, M. E., Kyrou, I., Flessa, C., Chatzigeorgiou, A., Oikonomou, E. K., Lambadiari, V., Randeva, H. S., & Kassi, E. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041589 · Cited by 37
“Additionally, homozygote carriers of this allele show increased HCC risk in MASLD patients [80].”
InfluentialLallukka, S., Sädevirta, S., Kallio, M. T., Luukkonen, P. K., Zhou, Y., Hakkarainen, A., Lundbom, N. M. I., Orho‐Melander, M., & Yki‐Järvinen, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-14706-0 · Cited by 35
“We also obtained blood samples for genotyping study subjects for NAFLD risk variants in PNPLA3 at rs738409, TM6SF2 at rs58542926 and MBOAT7 at rs641738.”
BackgroundInfluentialThe Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum
Vidal‐Cevallos, P., Sorroza-Martínez, A. P., Chávez-Tapia, N. C., Uribe, M., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084397 · Cited by 37
“The risk of HCC conferred by the PNPLA3 genotype is not solely mediated through progression to advanced fibrosis [41].”
BackgroundAn overview of the genetics, mechanisms and management of NAFLD and ALD
Rowell, R., & Anstee, Q. M. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-6-s77 · Cited by 35
Self-citationCaussy, C., Bhargava, M., Villesen, I. F., Gudmann, N. S., Leeming, D. J., Karsdal, M. A., Faulkner, C., Bao, D., Liu, A., Lo, M., et al. (2019) · Hepatology · doi:10.1002/hep.30610 · Cited by 33
The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics
Malladi, N., Alam, M. J., Maulik, S. K., & Banerjee, S. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106766 · Cited by 34
Wood, K. L., Miller, M. H., & Dillon, J. F. (2015) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2014-000019 · Cited by 29
“Miscellaneous TM6SF2 TM6SF2 encodes a transmembrane protein of unknown function;(9) the rs58542926 SNP in TM6SF2 is in strong linkage disequilibrium with the rs2228603 NCAN variant discussed above, and associations attributed to NCAN may relate instead to this variant.(84) Liu et al(84) studied the effect of the rs585…”
Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
Rios, R. S., Zheng, K. I., & Zheng, M.-H. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001888 · Cited by 29
“Some examples of studied SNPs are phospholipase domaincontaining 3 (PNPLA3),([57-59]) transmembrane 6 superfamily member 2 (TM6SF2),([58,60]) 17b-Hydroxysteroid dehydrogenase 13 (HSD17B13)([61,62]) and membrane-bound Oacyltransferase domain containing 7 (MBOAT7).”
BackgroundGenome‐Wide Association Study of Liver Fat: The Multiethnic Cohort Adiposity Phenotype Study
Park, S., Li, Y., Sheng, X., Hom, V., Xia, L. Y., Zhao, K., Pooler, L., Setiawan, V. W., Lim, U., Monroe, K. R., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1533 · Cited by 30
“(8) This variant has been replicated in two Chinese populations (MAF, 9%)(44,45) but not in two other studies with populations from China(46) and Latin America.”
BackgroundSen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104949 · Cited by 28
Self-citationNAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Cernea, S. (2024) · Life · doi:10.3390/life14020272 · Cited by 36
“TM6SF2 is a transmembrane protein involved in the secretion of VLDL cholesterol, and subsequent studies have associated this SNP with a higher risk of advanced fibrosis in patients with NAFLD, independent of other risk factors [60,68,69].”
BackgroundBerdowska, I., Matusiewicz, M., & Fecka, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062394 · Cited by 35
Chen, X., Zhou, P., Luo, D., Li, B., & Su, S. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.824 · Cited by 28
“Recently, two genome‐ wide association studies conducted by Kozlitina et al. (2014) and Liu et al. (2014) found that the transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 polymorphism (a functional variant that was associated with altered gene expression levels) was not only associated with…”
BackgroundWu, L., Liu, Y., Zhao, Y., Li, M., & Guo, L. C. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.04.009 · Cited by 29
Self-citationChen, H., Zhang, Y., Guo, T., Yang, F., Mao, Y., Li, L., Liu, C., Gao, H., Jin, Y., Che, Y., et al. (2020) · Liver International · doi:10.1111/liv.14616 · Cited by 27
The Genetic Architecture of Carbon Tetrachloride-Induced Liver Fibrosis in Mice
Tuominen, I., Fuqua, B. K., Pan, C., Renaud, N., Wroblewski, K., Civelek, M., Clerkin, K., Asaryan, A., Haroutunian, S. G., Loureiro, J., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.010 · Cited by 28
Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
Albhaisi, S. A. M., & Sanyal, A. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.665987 · Cited by 29
Racial differences in prevalence and severity of non-alcoholic fatty liver disease
Bonacini, M., Kassamali, F., Kari, S., Barrera, N. L., & Kohla, M. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i7.763 · Cited by 32
Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review
Sulaiman, S. A., Dorairaj, V., & Adrus, M. N. H. (2022) · Biomedicines · doi:10.3390/biomedicines11010106 · Cited by 33
Liver fat as risk factor of hepatic and cardiometabolic diseases
Demir, M., Bornstein, S. R., Mantzoros, C. S., & Perakakis, N. (2023) · Obesity Reviews · doi:10.1111/obr.13612 · Cited by 31
Rusu, I., Pirlog, R., Chiroi, P., Nutu, A., Puia, V. R., Fetti, A. C., Rusu, D. R., Berindan-Neagoe, I., & Al Hajjar, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012370 · Cited by 27
Arslanow, A., Stokes, C. S., Weber, S. N., Grünhage, F., Lammert, F., & Krawczyk, M. J. (2015) · Liver International · doi:10.1111/liv.12937 · Cited by 29
“Although it remains unclear whether the TM6SF2 variant is associated with both liver steatosis and fibrosis (22,37), our results underscore the genetic burden in carriers of the minor allele who are at risk of progressive liver injury in the setting of chronic liver diseases.”
BackgroundMíková, I., Neřoldová, M., Hubacek, J. A., Dlouhá, D., Jirsa, M., Honsová, E., Sticová, E., Lánská, V., Špičák, J., & Trunečka, P. (2019) · Transplantation · doi:10.1097/tp.0000000000002876 · Cited by 29
“167K variant was associated not only with more severe steatosis(22-25) but also with necroinflammation(23,25,26) and advanced fibrosis or cirrhosis.(22,23,26) A similar association has been reported in patients with chronic hepatitis C (HCV).”
BackgroundSerper, M., Vujković, M., Kaplan, D. E., Carr, R. M., Lee, K. M., Shao, Q., Miller, D. R., Reaven, P. D., Phillips, L. S., O’Donnell, C. J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237430 · Cited by 28
“…related traits such as serum alanine aminotransferase (ALT) concentration have identified 8 independent genetic loci derived primarily from hepatic lipid and glucose homeostatic genes ( LYPLAL1 , GCKR , HSD17B13 , TRIB1 , PPP1R3B , CPN1-ERLIN1-CHUK , TM6SF2 , PNPLA3 ) (S1 Table in S1 File) [3–18].”
Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
Dongiovanni, P., Meroni, M., Longo, M., Fargion, S. R., & Fracanzani, A. L. (2021) · Biomedicines · doi:10.3390/biomedicines9111524 · Cited by 30
“reported that the rs58542926 was associated with advanced hepatic fibrosis/cirrhosis in two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n = 1074) regardless of other confounders as gender, sex, body mass index (BMI), T2D and PNPLA3 rs738409 genotype [3…”
BackgroundLavrado, N., Salles, G. F., Cardoso, C. R. L., de França, P. H. C., Melo, M. F. D. G. G., Leite, N. C., & Villela‐Nogueira, C. A. (2024) · Liver International · doi:10.1111/liv.15845 · Cited by 28
Zeybel, M., Vatansever, S., Hardy, T., Sarı, A., Çakalağaoğlu, F., Avcı, A., Zeybel, G. L., Karahüseyinoğlu, S., Bashton, M., Mathers, J. C., et al. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0218-1 · Cited by 29
“(patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), seven-gene signatures) have been particularly associated with the susceptibility of advanced liver disease in non-alcoholic fatty liver disease and chronic hepatitis C infection [7–11].”
BackgroundMAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight
Pan, Z., Khatry, M. A., Yu, M., Choudhury, A. K., Sebastiani, G., Alqahtani, S. A., & Eslam, M. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241252543 · Cited by 31
Ueno, M., Takeda, H., Takai, A., & Seno, H. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i27.3410 · Cited by 29
From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria
Amorim, R., Magalhães, C. C., Borges, F., Oliveira, P. J., & Teixeira, J. (2023) · Biology · doi:10.3390/biology12040595 · Cited by 35
“TM6SF2 VLDL secretion rs58542926 Increased hepatic TG content and higher risk of advanced fibrosis in NAFLD; [31] Lower concentration of hepatic-derived TG-rich lipoproteins; [32] Impaired incorporation of polyunsaturated fatty acids into hepatic TGs, phospholipids, and cholesterol ester [20]”
BackgroundIntersecting Pathways: Nonalcoholic Fatty Liver Disease and Psoriasis Duet—A Comprehensive Review
Costache, D. O., Blejan, H., Cojocaru, D. L., Ioniță, G., Poenaru, M., Constantin, M. M., Costache, A. C., Căruntu, C., Balaban, D. V., & Costache, R. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052660 · Cited by 31
Sun, B., Ding, X., Tan, J., Zhang, J., Chu, X., Zhang, S., Liu, S., Zhao, Z., Xuan, S., Xin, Y., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0268 · Cited by 28
How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?
Mann, J. P., Semple, R. K., & Armstrong, M. J. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00145 · Cited by 32
“The risk allele is found in around 1% patients with NAFLD (55) and correlates positively with serum aminotransferase levels (33), hepatic steatosis (31), NASH activity, and fibrosis (but not HCC) (56).”
BackgroundBarbara, M., Scott, A. L., & Alkhouri, N. (2018) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.08.05 · Cited by 29
Ajmera, V., Liu, A., Bettencourt, R., Dhar, D., Richards, L., & Loomba, R. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16392 · Cited by 25
Chahal, D., Sharma, D., Keshavarzi, S., Arisar, F. A. Q., Patel, K., Xu, W., & Bhat, M. (2022) · Hepatology International · doi:10.1007/s12072-022-10304-z · Cited by 27
“It is possible these variants could be used to predict complications such as HCC [24, 25], or be targeted for therapeutic development.”
BackgroundCirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity
Jiao, J., Watt, G. P., Lee, M., Rahbar, M. H., Vatcheva, K. P., Pan, J., McCormick, J. B., Fisher‐Hoch, S. P., Fallon, M. B., & Beretta, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150978 · Cited by 27
“In NAFLD patients, carriers of the minor allele of non-synonymous SNP rs58542926 in transmembrane 6 superfamily member 2 (TM6SF2) were found to have an increased prevalence of advanced fibrosis [41].”
BackgroundGenetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
Chandrasekharan, K. H., & Alazawi, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01413 · Cited by 28
“…et al., 2014a) TM6SF2 E167K Increases levels of hepatic triglyceride content, ALT, and increased risk of hepatic fibrosis (Kozlitina et al., 2014; Liu et al., 2014b) MBOAT7 rs614738 Increases hepatic triglyceride content, and risk of hepatic steatosis, fibrosis, and HCC (Buch et al., 2015;…”
BackgroundInfluentialThe TM6SF2 Variants, Novel Genetic Predictors for Nonalcoholic Steatohepatitis
Roh, Y., Loomba, R. S., & Seki, E. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.11.014 · Cited by 23
Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health
Fierbinteanu-Braticevici, C. G., Sinescu, C. J., Moldoveanu, A. C., Petrişor, A., Diaconu, S., Crețoiu, D., & Braticevici, B. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9361-x · Cited by 23
“…with PNPLA3, other genetic risk factors such as TM6FS2 (E167K variant: substitution of lysine (E) to glutamic acid (K) at position 167) have been associated with both increased hepatic steatosis andwith an increased risk of developing advanced fibrosis (Dongiovanni et al. 2013; Liu et al. 2014).”
BackgroundTada, T., Nishimura, T., Yoshida, M., & Iijima, H. (2020) · Journal of Medical Ultrasonics · doi:10.1007/s10396-020-01058-y · Cited by 27
Noureddin, N., Noureddin, M., Singh, A., & Alkhouri, N. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-06955-x · Cited by 25
Constitutional and functional genetics of human alcohol‐related hepatocellular carcinoma
Nahon, P., & Nault, J. (2017) · Liver International · doi:10.1111/liv.13419 · Cited by 26
“Based on the predominant role of TM6SF2 variant, a role for the TM6SF2-T allele in the development of HCC was also suggested by a small-scale study conducted in NAFLD patients.(77) The combination of this genetic variant with PNPLA3 genotypes was recently associated with a higher rate of liver cancer in a European coh…”
Result
Metadata
- Authors
- Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., Donaldson, P., Aithal, G. P., Francque, S., Van Gaal, L., Clement, K., Ratziu, V., Dufour, J.-F., Day, C. P., Daly, A. K., & Anstee, Q. M.
- Affiliations
- Newcastle University (GB)
- Addenbrooke's Hospital (GB)
- University Hospital of Bern (CH)
- Inserm (FR)
- Nottingham University Hospitals NHS Trust (GB)
- Antwerp University Hospital (BE)
- Pitié-Salpêtrière Hospital (FR)
- Corresponding author
- Anstee, Quentin M.
- ORCID
- Venue
- Nature Communications
- Published
- 2014-06-30
- Volume
- 5
- Issue
- 1
- Pages
- 4309-4309
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4279183
- OpenAlex
- W2038831349
- Cited by
- 623
- References
- 45
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 50 · 2023: 51 · 2022: 56 · 2021: 61 · 2020: 82 · 2019: 49 · 2018: 50 · 2017: 45 · 2016: 54 · 2015: 50 · 2014: 11
- FWCI
- 40.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Open Access CRIS of the University of Bern
- Funders
- National Institute for Health and Care Research (FP7/2007–2013)
- European Commission (2007–2013, FP7 2007-2013, FP7/2007, 241762)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- TM6SF2, rs58542926, non-alcoholic fatty liver disease, liver fibrosis, liver cirrhosis, non-synonymous polymorphisms, genetic association, hepatic triglyceride content, neurocan, chromosome 19, steatohepatitis, PNPLA3, disease progression
- MeSH terms
- Adult, Aged, Alleles, Female, Genotype, Heterozygote, Humans, Liver, Liver Cirrhosis, Male, Membrane Proteins, Middle Aged, Nerve Tissue Proteins, Chondroitin Sulfate Proteoglycans, Cohort Studies, Disease Progression, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Lectins, C-Type, Neurocan, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.